MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells

MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells

Background The MUC1-C protein evolved in mammals to protect barrier tissues from loss of homeostasis; however, MUC1-C promotes oncogenesis in association with chronic inflammation. Aberrant expression of MUC1-C in cancers has been linked to depletion and dysfunction of T cells in the tumor microenvi...

Full description

Bibliographic Details
Main Authors:	Satoshi Ishikawa, Donald Kufe, Constantine Mitsiades, Nami Yamashita, Atsushi Fushimi, Atrayee Bhattacharya, Yoshihiro Morimoto, Tatsuaki Daimon, Haruka Hirose, Shizuka Yamano, Naoki Haratake, Rehan Ahmad, Hidekazu Takahashi, Olga Dashevsky
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-02-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/11/2/e006238.full

Similar Items

MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells
by: Tatsuaki Daimon, et al.
Published: (2024-01-01)

MUC1-C intersects chronic inflammation with epigenetic reprogramming by regulating the set1a compass complex in cancer progression
by: Atrayee Bhattacharya, et al.
Published: (2023-10-01)

MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells
by: Nami Yamashita, et al.
Published: (2023-11-01)

XIST and MUC1-C form an auto-regulatory pathway in driving cancer progression
by: Keyi Wang, et al.
Published: (2024-05-01)

MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer
by: Hiroki Ozawa, et al.
Published: (2024-07-01)

The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology
by: Florencia Secchiari, et al.
Published: (2022-12-01)

INHIBITION OF THE NKG2D ACTIVATING RECEPTOR EXPRESSION ON CYTOTOXIC LYMPHOCYTES BY RECOMBINANT MICA PROTEIN
by: E. V. Abakushina, et al.
Published: (2017-01-01)

The MICA‐129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation
by: Antje Isernhagen, et al.
Published: (2015-10-01)

MICA and NKG2D gene polymorphisms influence graft survival, and response to therapy in kidney transplantation
by: Roberto Littera, et al.
Published: (2024-11-01)

1355 DM919, an IND-ready MICA/B-specific antibody, reinforces NKG2D-MICA/B axis and promotes anti-tumor activities
by: Yi Xu, et al.
Published: (2023-11-01)

Shared epitope and polymorphism of MICA and NKG2D encoding genes in Greek and Polish patients with rheumatoid arthritis
by: Joanna Wielińska, et al.
Published: (2021-03-01)

Role of NKG2D-Expressing NK Cells and sMICA in Immune Surveillance of Advanced Lung Cancer
by: Jing LIANG, et al.
Published: (2009-01-01)

MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA
by: Younghoon Kim, et al.
Published: (2020-06-01)

The impact of NKG2A and NKG2D receptors and HLA-E and MICA ligands polymorphisms on post-transplant complications after paediatric allogeneic HSCT: a single-centre experience
by: Jagoda Siemaszko, et al.
Published: (2023-06-01)

Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
by: Eleme, K, et al.
Published: (2004)

MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia
by: Aaron D. Viny, et al.
Published: (2010-10-01)

Immunoassays for scarce tumour-antigens in exosomes: detection of the human NKG2D-Ligand, MICA, in tetraspanin-containing nanovesicles from melanoma
by: Sheila López-Cobo, et al.
Published: (2018-05-01)

Ganoderma lucidum Polysaccharide Enhanced the Antitumor Effects of 5-Fluorouracil against Gastric Cancer through Its Upregulation of NKG2D/MICA
by: Xi Yang, et al.
Published: (2019-01-01)

Novel role of immune-related non-coding RNAs as potential biomarkers regulating tumour immunoresponse via MICA/NKG2D pathway
by: Jing Zhang, et al.
Published: (2023-10-01)

Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment
by: Tristan Courau, et al.
Published: (2019-03-01)

NKG2D
by: O'Callaghan, C
Published: (2009)

KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP
by: Reem Alkhayer, et al.
Published: (2023-05-01)

MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer
by: Audrey Bouillez, et al.
Published: (2017-09-01)

The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
by: Ge Tan, et al.
Published: (2023-08-01)

Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis
by: Lin Yang, et al.
Published: (2025-02-01)

MICA-specific nanobodies for diagnosis and immunotherapy of MICA+ tumors
by: Elisha R. Verhaar, et al.
Published: (2024-03-01)

Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis
by: Jesús K. Yamamoto-Furusho, et al.
Published: (2015-01-01)

Preclinical characterization of Pan-NKG2D ligand-binding NKG2D receptor decoys
by: Peter B. Rupert, et al.
Published: (2024-04-01)

Degradation of MUC7 and MUC5B in human saliva.
by: Sachiko Takehara, et al.
Published: (2013-01-01)

Synthetic mica
by: Insloy, et al.
Published: (1950-11-01)

Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)
by: Melek BUYUK, et al.
Published: (2023-01-01)

Clinicopathological Study of Carcinoma of the Ampulla of Vater with Special Reference to MUC1, MUC2 and MUC5AC Expression
by: Maithili Mandar Kulkarni, et al.
Published: (2017-05-01)

Diethyldithiocarbamate-copper complex ignites the tumor microenvironment through NKG2D-NKG2DL axis
by: Daciana C. Dumut, et al.
Published: (2025-02-01)

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
by: Hiraki, Masayuki, et al.
Published: (2020)

MUC1 and MUC16: critical for immune modulation in cancer therapeutics
by: Xinyi Chen, et al.
Published: (2024-02-01)

Immunohistochemical detection of MUC5AC and MUC5B mucins in ferrets
by: David K. Meyerholz, et al.
Published: (2023-06-01)

Comparison of the transmembrane mucins MUC1 and MUC16 in epithelial barrier function.
by: Ilene K Gipson, et al.
Published: (2014-01-01)

Mechanisms of NKG2D ligand regulation
by: McCarthy, M, et al.
Published: (2013)

Inhibitory NKG2A+ and absent activating NKG2C+ NK cell responses are associated with the development of EBV+ lymphomas
by: Hannes Vietzen, et al.
Published: (2023-06-01)

Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
by: Tobias Zöller, et al.
Published: (2018-03-01)